NCT07082205View on ClinicalTrials.gov

Monoclonal Antibodies in Children With Severe Anaemia or Severe Malaria to Prevent Malaria After Hospital Discharge

PHASE3RecruitingINTERVENTIONAL
Enrollment

398

Participants

Timeline

Start Date

May 2, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

April 30, 2027

Conditions
MalariaSevere MalariaSevere AnaemiaPost Discharge
Interventions
BIOLOGICAL

Antimalarial monoclonal antibodies

L9LS Antimalarial monoclonal antibodies (mMAbs)

DRUG

Dihydroartemisinin - Piperaquine (DP)

Post-Discharge Malaria Chemoprevention

BIOLOGICAL

Placebo mMAB

Placebo anti malarial monoclonal antibody (placebo mMAB) which is Normal saline

DRUG

Placebo PDMC

Placebo PDMC course which comprises placebo DP oral tablets

Trial Locations (2)

40300

RECRUITING

HomaBay County Teaching and Referral Hospital, Kisumu

40600

RECRUITING

Siaya County Referral Hospital, Kisumu

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Centers for Disease Control and Prevention

FED

lead

Liverpool School of Tropical Medicine

OTHER